Which Anti-VEGF Therapy (Ranibizumab, Bevacizumab, or Aflibercept) Demonstrates The Most Cost-Effective Outcomes For Treating Age-Related Macular Degeneration ? : A Systematic Review. the. Indonesian. j. gen. med. 2025;12(3):1-48. doi:10.70070/vbsedq58